I'm glad most of you like the new design. For those who preferred the old one, don't worry. I'm working on an alternate stylesheet that will have the same look (you will be able to switch to it, and it'll remember your preference). No ETA on that, as I'm quite busy.

Some links (yeah, as usual, saturday is a slow news day) :

- Visualizing Antibiotic Resistance
- Biophotonics technology harnesses power of light
- No evidence that calcium and vitamin D prevent fractures
- Study shows genes predict how well diabetes drug will work
- Sydney team invents a 3D hearing aid
- Generex begins testing new vaccine for breast cancer patients
- Researchers show protein's role in stopping bacterial-induced inflammation
- AECOM activates longevity gene
- Robots confirm global warming

Kinovate Life Sciences, Inc, a provider of tools for oligonucleotide synthesis and gene delivery, announced today that it will officially launch its new NittoPhase™ solid support for oligonucleotide synthesis at the TIDES meeting commencing in Boston on May 1st. The joint development of this solid phase support product was announced on November 8th, 2004 by Kinovate’s sole shareholder, Nitto Denko Corporation (Osaka, Japan), a leading multi-national polymer synthesis company and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), a leader in RNA-based drug discovery and development.

Some structural and functional measures of cardiovascular disease risk may improve by the eighth week of a diet and exercise regimen, according to a study presented today at the American Heart Association's Sixth Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.